A patient death in a phase 1 trial of Mersana Therapeutics’ antibody-drug ... which is developing the STING agonist in collaboration with GSK under the terms of a $1.3 billion option deal ...
Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...
Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...
Mersana plans to continue enrolling patients in dose escalation and expects to present initial clinical pharmacodynamic STING activation data for XMT-2056 in 2025. Mersana continues to advance its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback